Literature DB >> 19906037

Improvement of an ultrasensitive human immunodeficiency virus type 1 real-time reverse transcriptase-polymerase chain reaction targeting the long terminal repeat region.

Anke Edelmann1, Ulrich Kalus, Anke Oltmann, Angela Stein, Anett Unbehaun, Christian Drosten, Detlev H Krüger, Jörg Hofmann.   

Abstract

BACKGROUND: Human immunodeficiency virus Type 1 (HIV-1) assays applying nucleic acid testing (NAT) rely on HIV-1 sequence-specific primers and probes. Their hybridization can be limited or abolished by genetic polymorphisms occurring in the target sequence. STUDY DESIGN AND METHODS: Blood donations are routinely tested for HIV-1/2 antibodies and for HIV-1 RNA in our blood transfusion unit. Recently, HIV-1 RNA was undetectable with an established in-house real-time long terminal repeat (LTR) reverse transcriptase-polymerase chain reaction (RT-PCR) in two cases, whereas serologic assays were positive. The reason for this discrepancy was elucidated by sequencing of the NAT target region in the respective single donations. An improved primer was designed and tested on HIV-1 reference panels and blood donations to ensure reliable detection of HIV-1 RNA.
RESULTS: Direct sequencing of the target region, isolated from samples of two unrelated HIV-positive blood donors, revealed one and four mismatches in the hybridization domain of the forward primer, respectively. Both viruses belong to HIV-1 Subtype B. LTR RT-PCR with an additional forward primer was suitable for all strains of HIV-1 tested with high sensitivity.
CONCLUSIONS: Surveillance of HIV-1 genetic diversity is essentially required to continually evaluate its impact on performance of diagnostic and patient monitoring assays.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19906037     DOI: 10.1111/j.1537-2995.2009.02477.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  6 in total

1.  Pilot studies for development of an HIV subtype panel for surveillance of global diversity.

Authors:  Mark Manak; Silvana Sina; Bharathi Anekella; Indira Hewlett; Eric Sanders-Buell; Viswanath Ragupathy; Jerome Kim; Marion Vermeulen; Susan L Stramer; Ester Sabino; Piotr Grabarczyk; Nelson Michael; Sheila Peel; Patricia Garrett; Sodsai Tovanabutra; Michael P Busch; Marco Schito
Journal:  AIDS Res Hum Retroviruses       Date:  2012-02-24       Impact factor: 2.205

2.  Risk Minimization Measures for Blood Screening HIV-1 Nucleic Acid Amplification Technique Assays in Germany.

Authors:  Michael Chudy; Julia Kress; Jochen Halbauer; Margarethe Heiden; Markus B Funk; C Micha Nübling
Journal:  Transfus Med Hemother       Date:  2013-12-19       Impact factor: 3.747

Review 3.  Molecular virology in transfusion medicine laboratory.

Authors:  Daniel Candotti; Jean-Pierre Allain
Journal:  Blood Transfus       Date:  2012-12-21       Impact factor: 3.443

4.  Implementation of an HIV-1 Triple-Target NAT Assay in the Routine Screening at Three German Red Cross Blood Centres.

Authors:  Silke De Zolt; Rolf Thermann; Thorsten Bangsow; Lutz Pichl; Benjamin Müller; Christine Jork; Marijke Weber-Schehl; Doris Hedges; Ingo Schupp; Patrick Unverzagt; Katrin de Rue; W Kurt Roth
Journal:  Transfus Med Hemother       Date:  2016-05-11       Impact factor: 3.747

5.  Development and Evaluation of a Duo Chikungunya Virus Real-Time RT-PCR Assay Targeting Two Regions within the Genome.

Authors:  Laurence Thirion; Laura Pezzi; Iban Corcostegui; Audrey Dubot-Pérès; Alessandra Falchi; Xavier de Lamballerie; Remi N Charrel
Journal:  Viruses       Date:  2019-08-15       Impact factor: 5.048

6.  Investigation of Human Cancers for Retrovirus by Low-Stringency Target Enrichment and High-Throughput Sequencing.

Authors:  Lasse Vinner; Tobias Mourier; Jens Friis-Nielsen; Robert Gniadecki; Karen Dybkaer; Jacob Rosenberg; Jill Levin Langhoff; David Flores Santa Cruz; Jannik Fonager; Jose M G Izarzugaza; Ramneek Gupta; Thomas Sicheritz-Ponten; Søren Brunak; Eske Willerslev; Lars Peter Nielsen; Anders Johannes Hansen
Journal:  Sci Rep       Date:  2015-08-19       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.